Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

Management believes that the Company’s existing cash resources

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
arvitar Member Profile
 
Followed By 52
Posts 14,297
Boards Moderated 0
Alias Born 01/19/09
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2020 4:11:11 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/22/2020 6:02:22 AM
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2using Human Coronavi... InvestorsHub NewsWire - 5/20/2020 6:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/19/2020 5:15:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2020 5:01:26 PM
NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses InvestorsHub NewsWire - 5/12/2020 7:02:12 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/1/2020 3:39:49 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/3/2020 6:01:26 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/24/2020 5:02:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2020 3:15:50 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/19/2020 6:04:12 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/14/2020 5:54:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/11/2020 4:31:30 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 2/5/2020 4:22:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2020 6:11:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2020 5:12:40 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/27/2020 12:12:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/24/2020 4:13:38 PM
Prospectus Filed Pursuant to Rule 424(b)(1) (424b1) Edgar (US Regulatory) - 1/24/2020 6:03:05 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/10/2020 6:01:05 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/8/2020 5:15:55 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/7/2020 6:02:23 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/2/2020 12:40:33 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/23/2019 12:52:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/19/2019 4:47:27 PM
arvitar   Thursday, 11/16/17 02:30:29 PM
Re: Nanotoday post# 136141
Post # of 143833 
Quote:
Management believes that the Company’s existing cash resources are sufficient for its operations at the current rate of expenditures to continue through November 2018. However, management believes that the available funds are insufficient for the Company’s projected work, which is beyond normal pre-clinical development operations, leading towards an Investigational New Drug Application (IND) filing with the U.S. Food and Drug Administration (FDA), to continue through November 2018.
p.10 https://ih.advfn.com/p.php?pid=nmona&article=76095857




Either some months or years after they've raised more cash, or never. At least according to the company.


"When do you think Tox will be completed? "

A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist